https://wealthcreatures.com/2020/04/16/power-mech-projects-can-it-again-powerup/
POWER MECH
DEEPLY UNDERVALUED
RE RATING CANDIDATE VERY 🔜🔜
VALUE BUYING CAN EMERGE
POWER MECH
DEEPLY UNDERVALUED
RE RATING CANDIDATE VERY 🔜🔜
VALUE BUYING CAN EMERGE
WealthCreatures
POWER MECH PROJECTS – Can It Again Powerup??
CMP – 336MARKET CAP – 490 crBOOK VALUE – 56252wk HIGH/LOW – 1175/3065 Year HIGH/LOW – 1175/306FACE VALUE – 10DIVIDEND YIELD – 0.30%FY20 EXPECTED EPS –…
Wealthcreatures.com
1⃣ NATIONAL PEROXIDE VALUE BUYING EMERGING FROM SUPPORT LEVELS OF 1850 TO 1900 STOCK BOUNCING BACK NATIONAL PEROXIDE TO ANNOUNCE ITS Q2 NUMBERS ON 21st OCTOBER 2⃣ BHARAT RASAYAN IN ACCMULATION ZONE NEAR 8500
BHARAT RASAYAN
ONCE CLOSED ABOVE 10100 READY FOR NEW 52WK HIGH VERY SOON
ONCE CLOSED ABOVE 10100 READY FOR NEW 52WK HIGH VERY SOON
Wealthcreatures.com
NIFTY GREEN TO ❤️ 13145 TO 12984 CAN TOUCH 12950/12900 TODAY ITSELF
NIFTY LOW 12962
NIFTY IF CLOSES ABOVE 13000
POSSIBLE RE TEST 13050/13145
CONCENTRATE ON STOCK SPECIFIC IDEAS 💡 ONLY
NIFTY IF CLOSES ABOVE 13000
POSSIBLE RE TEST 13050/13145
CONCENTRATE ON STOCK SPECIFIC IDEAS 💡 ONLY
Wealthcreatures.com
KEEP THIS IN MIND NIFTY NEW HIGH COMING NEAR 13190/13290 +/- 1% CAN BE TOP FOR NEAR TERM STAY CAUTIOUS BULL RIDE THE TREND & RALLY CORRECTION WLD BE SHORT LIVED TREND WLD CHANGE IN NIFTY ONLY ON CLOSE BELOW 12800/12700
NIFTY
💔💔
13145 TO 12900
GAVE CAUTIOUS VIEW ALERT
WHEN NIFTY WAS ON TOP
NOW NIFTY BELOW 12900
💔💔
13145 TO 12900
GAVE CAUTIOUS VIEW ALERT
WHEN NIFTY WAS ON TOP
NOW NIFTY BELOW 12900
Wealthcreatures.com
WONT BE ABLE TO PROVIDE UPDATE FOR NEXT 2 TO 3 DAYS NIFTY P/E - 34.93 STAY ALERT 📢 KEEP BOOKING PROFITS AS PER RISK IN INDIVIDUAL STOCKS TIME TO BOOK ATLEST 50% PROFITS & SIT ON CASH. KEEP RIDING TRADING BETS WITH S/L AND GO WITH TREND.RIDE THE…
NIFTY TOP - 13145
OUR 1ST RESISTANCE WAS 13140
EXACT FROM TOP U TURN FOR NIFTY
OUR 1ST RESISTANCE WAS 13140
EXACT FROM TOP U TURN FOR NIFTY
Wealthcreatures.com
LONGTERM PICK TANLA SOLUTION 6X RETURNS IN JUST 15 MONTHS 59 TO 325
TANLA SOLUTION
ALMOST 10x RETURNS IN JUST 16 MONTHS
58.50 TO 555.90
POSSIBLE # 666/777
KEEP BOOKING PROFITS AS PER RISK
ALMOST 10x RETURNS IN JUST 16 MONTHS
58.50 TO 555.90
POSSIBLE # 666/777
KEEP BOOKING PROFITS AS PER RISK
POLYCAP
CMP - 925
ACCMULATION - 900 TO 925
SUPPORT @890
TEST LEVELS - 950/990/1040++
S/L - 880 cbsl basis or as per Risk
CMP - 925
ACCMULATION - 900 TO 925
SUPPORT @890
TEST LEVELS - 950/990/1040++
S/L - 880 cbsl basis or as per Risk
Wealthcreatures.com
https://wealthcreatures.com/2020/04/16/power-mech-projects-can-it-again-powerup/ POWER MECH DEEPLY UNDERVALUED RE RATING CANDIDATE VERY 🔜🔜 VALUE BUYING CAN EMERGE
KEEP ON RADAR
ONCE CLOSED ABOVE 435 WE CAN SEE BIG UPMOVE
ONCE CLOSED ABOVE 435 WE CAN SEE BIG UPMOVE
Laurus Labs CEO Says Richcore Lifesciences’ Acquisition Will Fast-Track Biotech Ambitions
Pharmaceutical ingredients maker Laurus Labs Ltd. has found its “fourth lever of growth” in the biotech space, according to its Chief Executive Satyanarayana Chava, and its most recent acquisition will fast-track this ambition.
“The gestation period to enter the biotech space is a 6-7-year period,” he told BloombergQuint’s Menaka Doshi in an interview. “Our idea is to cut down this gestation period significantly by making an acquisition.”
Laurus Labs, on Nov. 26, closed a Rs 250-crore deal to acquire a majority stake in Richcore Lifesciences, marking its entry into the biotech space and adding to its existing three divisions - active pharmaceutical ingredients, formulations and synthesis.
The startup’s promoters and management will continue to run the business while Laurus Labs—having acquired just over 72% stake—will allow the company to scale its manufacturing.The acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. Following the successful closure of the transaction, Richcore will be renamed as Laurus Bio Pvt.
Chava expects a significant return from the investment to come from Richcore’s contract manufacturing of recombinant proteins. The startup’s first large-scale facility —with a 2,50,000 litre capacity—will be ready by March 2021.
“That’s where the quantum jump in revenues will come from.” Richcore clocked Rs 30 crore revenue in its first six months of this financial year.
Another such facility is slated to be built by the end of 2021.
View: Positive for Lauras Lab in longer run.
Pharmaceutical ingredients maker Laurus Labs Ltd. has found its “fourth lever of growth” in the biotech space, according to its Chief Executive Satyanarayana Chava, and its most recent acquisition will fast-track this ambition.
“The gestation period to enter the biotech space is a 6-7-year period,” he told BloombergQuint’s Menaka Doshi in an interview. “Our idea is to cut down this gestation period significantly by making an acquisition.”
Laurus Labs, on Nov. 26, closed a Rs 250-crore deal to acquire a majority stake in Richcore Lifesciences, marking its entry into the biotech space and adding to its existing three divisions - active pharmaceutical ingredients, formulations and synthesis.
The startup’s promoters and management will continue to run the business while Laurus Labs—having acquired just over 72% stake—will allow the company to scale its manufacturing.The acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. Following the successful closure of the transaction, Richcore will be renamed as Laurus Bio Pvt.
Chava expects a significant return from the investment to come from Richcore’s contract manufacturing of recombinant proteins. The startup’s first large-scale facility —with a 2,50,000 litre capacity—will be ready by March 2021.
“That’s where the quantum jump in revenues will come from.” Richcore clocked Rs 30 crore revenue in its first six months of this financial year.
Another such facility is slated to be built by the end of 2021.
View: Positive for Lauras Lab in longer run.
Wealthcreatures.com
IGL Accumulate 405 -409 Bigger Horizon SL 378 Short term 395 Advisable for A bit long TF T 440 / 490
IGL
10 % UPPER CIRCUIT
492
ALL TARGETS ACHIVED FOR SHORT TERM
BOOK PROFITS OR TRAIL WITH S/L 470 FOR NEXT T - 525/555++
10 % UPPER CIRCUIT
492
ALL TARGETS ACHIVED FOR SHORT TERM
BOOK PROFITS OR TRAIL WITH S/L 470 FOR NEXT T - 525/555++